US$ 20.64
merck glp-1 agonist Receptor Agonists: The New Wave in Diabetes Management A Closer Look at the
Description
Jean-Pierre Raufman was a freshly minted gastroenterologist when he arrived at the National Institutes of Health (NIH) in Bethesda, Maryland, in July 1980

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Hepatology 2010;51:15841592

doi: 10.1210/jc.2016-1933

Gault VA, Kerr BD, Harriott P, Flatt PR (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity

Adv Exp Med Biol 2021;1307:171-192
